Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.48 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12126117 | 0.83 | PRCP (0.55) | OPRM1OPRK1PRCPCYP2D6 | |
| SCHEMBL4880438 | 0.83 | HCRTR1 (0.51) | OPRM1OPRK1HDAC8HCRTR1HCRTR2 | |
| SCHEMBL29159488 | 0.82 | OPRM1 (0.54) | OPRM1OPRK1PRCPHDAC8CYP2D6 | |
| SCHEMBL12124978 | 0.79 | PRCP (0.56) | OPRM1OPRK1PRCPCYP2D6 | |
| SCHEMBL11784786 | 0.78 | MTNR1B (0.48) | OPRM1OPRK1MTNR1BOPRD1CYP2D6 | |
| SCHEMBL14417432 | 0.75 | OPRM1 (0.48) | OPRM1OPRK1PRCPOPRD1CYP2D6 | |
| SCHEMBL12125928 | 0.73 | PRCP (0.59) | OPRM1OPRK1PRCPMTNR1BOPRD1 | |
| SCHEMBL9541988 | 0.73 | OPRM1 (0.53) | OPRM1OPRK1PRCPHDAC8CYP2D6 | |
| SCHEMBL8820261 | 0.72 | OPRM1 (0.50) | OPRM1OPRK1PRCPOPRD1 | |
| SCHEMBL8560553 | 0.72 | OPRM1 (0.49) | OPRM1OPRK1PRCPHDAC8MTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7271270-B2 | High affinity small molecule C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070027158-A1 | High affinity small molecule C5a receptor modulators | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
| US-6884815-B1 | High affinity small molecule C5a receptor modulators | NEUROGEN CORPORATION (US) | 2005-04-26 | — | — | US | disclosed |
| EP-1322309-A4 | HIGH AFFINITY SMALL MOLECULE C5A RECEPTOR MODULATORS | NEUROGEN CORP (US) | 2004-10-13 | — | — | EP | disclosed |
| US-6723743-B1 | TREATING PATIENT SUFFERING FROM RHEUMATOID ARTHRITIS, PSORIASIS, BRONCHIAL ASTHMA, ALZHEIMER'S DISEASE, MYOCARDIAL INFARCTION OR ATHEROSCLEROSIS | NEUROGEN CORPORATION | 2004-04-20 | — | — | US | disclosed |
| EP-1322309-A2 | HIGH AFFINITY SMALL MOLECULE C5A RECEPTOR MODULATORS | Neurogen Corporation (US) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002049993-A2 | HIGH AFFINITY SMALL MOLECULE C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027158-A1 | High affinity small molecule C5a receptor modulators | C3AR1, C5AR1, C5AR2 | OPRM1 135/4885OPRK1 286/4885PRCP 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.